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Background aims. Cord blood (CB) and amniotic fluid (AF) could represent new and attractive mesenchymal stromal cell
(MSC) sources, but their potential therapeutic applications are still limited by lack of standardized protocols for isolation and
differentiation. In particular, chondrogenic differentiation has never been deeply investigated.Methods.MSCs were obtained
from CB and AF samples collected during cesarean sections at term and compared for their biological and differentiation
properties, with particular interest in cartilage differentiation, in which quantitative real-time polymerase chain reaction and
immunohistochemical analyses were performed to evaluate the expression of type 2 collagen, type 10 collagen, SRY-box9
and aggrecan. Results.We were able to isolate MSCs from 12 of 30 (40%) and 5 of 20 (25%) CB and AF units, respectively.
Fluorescence in situ hybridization analysis indicated the fetal origin of isolated MSC strains. Both populations expressed
mesenchymal but not endothelial and hematopoietic markers, even though we observed a lower expression of human
leukocyte antigen (HLA) I in CB-MSCs. No differences in proliferation rate and cell cycle analysis could be detected. After
osteogenic induction, both populations showed matrix mineralization and typical marker expression. Under chondrogenic
conditions, pellets derived from CB-MSCs, in contrast with AF-MSCs pellets, were significantly larger, showed cartilage-like
morphology and resulted positive for chondrocyte-associated markers, such as type 2 collagen, type 10 collagen, SRY-box9
and aggrecan. Conclusions. Our results show that CB-MSCs and AF-MSCs collected at term differ from each other in their
biological and differentiation properties. In particular, only CB-MSCs showed a clear chondrogenic potential and thus could
represent an ideal candidate for cartilage-tissue engineering.
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Mesenchymal stromal cells (MSCs) are multipotent
non-hematopoietic progenitors characterized by
plastic adhesion, expression of a specific panel of
surface antigens and capacity to differentiate into
mesenchymal lineages, specifically bone, cartilage
and adipose tissue (1e3). For these reasons, MSCs*These authors contributed equally to this work.
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repair and regenerative medicine (4,5). MSCs were
initially isolated from bone marrow (BM) by Frie-
denstein et al. (6). Although it has been considered
for years the main source of MSCs for both experi-
mental and clinical applications, the use of BM-
MSCs has disadvantages. First, the procedure fornti Research Center, Pediatric Department, University of Milano-Bicocca,
gmail.com
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invasive and painful. Furthermore, frequency, pro-
liferation and differentiation potential of BM-MSCs
decrease with increasing donor age (4). As a conse-
quence, alternative sources from adult and, more
importantly, perinatal tissues, have been considered.
Among these sources, cord blood (CB) and amniotic
fluid (AF), usually regarded as medical waste, could
represent new and attractive MSC sources because
of their advantages over BM. A large amount of
samples can be easily obtained at delivery, with no
risk to the donor. Moreover, perinatal tissueederived
MSCs have many advantageous features, such as
high proliferation capacity and differentiation po-
tential as the result of their ontogenically younger
origin, and no donor age-dependent variations (7).
These cells could also be useful for development of in
utero stem cell transplantation strategies. Several
studies have demonstrated that fetal MSCs harvested
in the prenatal period can be processed during the
remainder of gestation to obtain autologous tissues
for the repair of congenital anomalies soon after birth
or in utero (8e10). Despite this evidence, clinical
application of AF-MSCs and CB-MSCs has not yet
been achieved, mainly because of the low success
rate of isolation. Moreover, the application of these
cells for transplant purposes requires extensive
characterization, standardization of reproducible
differentiation protocols and functional character-
ization of the differentiated cells. Interestingly, recent
studies have shown that MSCs isolated from several
prenatal sources represent heterogeneous pop-
ulations, whose principal differences depend on the
source and the donor (11e15).
MSCs are a promising cell source for cartilage
tissue engineering, given their chondrogenic poten-
tial. Recently, an increasing number of studies have
described that specific properties of MSCs, including
chondrogenic capability, are dependent on their
origin. In fact, it has been previously demonstrated
that MSCs isolated from different tissues do not
represent identical cell populations but vary in the
expression profile of some growth factors relevant for
chondrogenesis (12,16e22). Considering these as-
pects, we hypothesized that the frequency of fetal
MSCs correlates with clinical parameters and that
term CB-MSCs and AF-MSCs may display differ-
ences in their differentiation potential. Therefore, the
objectives of this study were to analyze a possible
correlation between clinical parameters and the suc-
cess rate of fetal MSCs isolation, to compare the
biological properties of fetal MSCs isolated from term
CB and AF samples and, more specifically, to eval-
uate their capability into cartilage differentiation.
Chondrogenic differentiation was induced by means
of a three-dimensional pellet culture systemsubmitted to specific stimuli and investigated through
histology, immunohistochemistry and gene expres-
sion studies of cartilage-associated markers.Methods
Specimen collection
Both CB and AF samples were collected from
volunteer donors during elective cesarean sections
at term (37e42 weeks of gestation) at the San
Gerardo Hospital (Monza, Italy). Exclusion criteria
for collection were presence of clinical cho-
rioamnionitis, prenatally diagnosed chromosome
abnormalities and severe oligohydramnios. AF was
collected by means of amniotic puncture after
transversal incision of the myometrium layer of the
lower uterine segment and stored in sterile tubes.
CB was collected immediately after delivery of
the infant and cord clamping, before the delivery
of placenta, and stored in bags (MacoPharma,
Rho, Italy) with anticoagulant (citrate-phosphate-
dextrose buffer). Collections were performed after
maternal consent was given and in accordance with
the ethical standards of the hospital ethics com-
mittee. Clinical information from each donor was
prospectively collected and included date of de-
livery, gestational age, maternal characteristics, sex
and birth weight of the infant and pregnancy details.Isolation and culture of human MSCs from CB and AF
Mononuclear cells (MNCs) were isolated from
whole CB by means of density gradient centrifuga-
tion with the use of Ficoll-Hypaque-Plus solution
(GE Healthcare, Little Chalfont, Buckinghamshire,
UK). The colony-forming unit fibroblast (CFU-F)
assay was performed as follows. MNCs were counted
with the use of an automated cell counter (Coulter
AcT Diff, Beckman Coulter, Brea, CA, USA) and
placed in culture at 37C in a humidified atmosphere
containing 5% CO2 at a density of 2  106 cells/cm2
into culture dishes (100-mm diameter; Nunc,
Rochester, MN, USA) in Dulbecco’s modified Ea-
gle’s medium (DMEM)elow glucose (Invitrogen,
Carlsbad, CA, USA) supplemented with 20% fetal
bovine serum (FBS) (Biosera, Ringmer, UK), 1%
penicillin-streptomycin (Invitrogen) and 1% L-
glutamine (Invitrogen). Dexamethasone (DEX; 107
mol/L) (Sigma-Aldrich, St Louis, MO, USA) was
added in the primary culture medium for 1 week.
Non-adherent cells were removed 48 h after initial
plating. After 17 days of culture in medium, CFU-F
colonies were scored at 20 magnification. The
cultures, consisting of adherent cells, were main-
tained in basal medium until they reached 70%
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trypsin (Invitrogen). For subsequent expansion, cells
were counted on a hemocytometer and re-plated at a
density of 2  103cells/cm2 and maintained in cul-
ture for several passages.
AF specimens were centrifuged and cells were
re-suspended in DMEMelow glucose supplemented
with 20% FBS, 1% penicillin-streptomycin and 1%
L-glutamine, seeded at a concentration of 1 
106cells/cm2 and incubated at 37C in 5% CO2 air
atmosphere. After 17 days of culture in medium,
CFU-F colonies were scored at 20 magnification.
Subsequently, adherent cells were cultured in the
same conditions as CB-MSCs.Proliferation kinetics of MSCs
The cumulative population doubling (PD) levels at
each sub-cultivation were calculated from the cell
count by use of the equation: PDn¼ PDne1þ[log(C1/
C0)]/log2, wherein C0 ¼ cells number initially seeded
and C1 ¼ cells number harvested. The PDs of cells
from P2 to P9were determined. Three sets of cultures
were repeated for each sample. The living cell count
was performed in a hemocytometer by means of try-
pan blue dye exclusion (Sigma-Aldrich).Fluorescence in situ hybridization analysis
CB-MSCs and AF-MSCs isolated from male infants
were used to assess contamination of maternal cells.
Fluorescence in situ hybridization analysis (FISH)
was performed with the use of CEP X (DXZ1)
SpectrumGreen/CEP Y (DYZ3) SpectrumOrange
probes (Abbott Molecular, Des Plaines, IL, USA).Karyotype analysis
MSCs were cultured in medium supplemented with
10 mL/mL of colcemid (10 g/mL, Sigma-Aldrich)
for up to 6 h. Conventional cytogenetics was per-
formed by the standard procedures and QFQ band-
ing (Q-bands by fluorescence with the use of
quinacrine).Flow cytometric analysis
CB-MSCs and AF-MSCs at passage 3 were labeled
with phycoerythrin-conjugated or fluorescein iso-
thiocyanateeconjugated antibodies against CD14
(clone 61D3; eBioscience, San Diego, CA, USA),
CD34 (clone 581; BD Biosciences, San Jose, CA,
USA), CD45 (clone HI30; BD Biosciences), CD90
(clone 5E10; eBioscience), CD73 (clone AD2; BD
Biosciences), CD105 (clone SN6; eBioscience),
CD146 (clone P1H12; BD Biosciences), humanleukocyte antigen (HLA)-ABC (HLA I, clone G46-
2.6; BD Biosciences), HLA-DR (HLA II, clone
G46-6; BD Biosciences), CD31 (clone L133.1; BD
Biosciences), CD144 (clone No. 123413, R and D,
Minneapolis, MN, USA), vascular endothelial
growth factorereceptor 1 (VEGF-R1) (clone No.
49560; R & D) and VEGF-receptor 2 (VEGF-R2)
(clone No. 89106, R and D). Isotype antibodies were
used as control. Fluorescence-activated cell sorting
(FACS) analysis was performed on three CB-MSCs
and three AF-MSCs lines, which were selected
randomly. Flow cytometric analysis was performed
on 20,000 events with the use of a FACScan cy-
tometer, and data were analyzed with the use of
CellQuest software (BD Biosciences).Cell cycle analysis
CB-MSCs and AF-MSCs at passage 4 were har-
vested 48, 96 and 144 h after seeding and were
washed twice with ice-cold phosphate-buffered saline
(Gibco, Grand Island, NY, USA). Cells were re-
suspended in GM saline solution (phosphate-
buffered saline 1 without CaMg, 1.1 g/L glucose,
0.5 mmol/L ethylenediaminetetra-acetic acid) and
permeabilized with ice-cold 70% ethanol, followed
by incubation with 2 mL of a solution containing 10
mg/mL propidium iodide plus 25 mL 1 mg/mL
RNAse 10,000 units overnight (23).
Flow cytometric analysis was performed on
20,000 events by use of a FACS Calibur (BD Bio-
sciences), and the cell cycle phase distribution was
calculated as percentages by a gaussian-modified
method (24).Osteogenic differentiation
CB-MSCs and AF-MSCs at passage 3 were seeded
at a density of 6  103 cells/cm2 in basal medium, as
previously described (25). After 48 h, medium was
switched to osteogenic induction medium consisting
of DMEMelow glucose (Invitrogen), supplemented
with 10% FBS (Biosera), 100 nmol/L DEX (Invi-
trogen), 10 mmol/L B-glycerol-phosphate (Invi-
trogen) and 0.05 mmol/L 2-phosphate-ascorbic acid
(Invitrogen). The osteogenic differentiation was
assessed through the use of alizarin red S (Sigma-
Aldrich) staining on day 21 of differentiation. On
days 0, 7, 14 and 21, transcript levels for the
following genes were analyzed by means of quanti-
tative real-time polymerase chain reaction (Q-RT-
PCR): alkaline phosphatase (ALPL), type I collagen
(COL1A2), osteonectin (OTN), runt-related tran-
scription factor 2 (RUNX2), osteopontin (OPN) and
osteocalcin (OTC).
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For the adipogenic differentiation, we referred to
Pittenger et al. (1). Briefly, CB-MSCs and AF-MSCs
at passage 3 were seeded at a density of 2  104 cells/
cm2 in basal medium. After 24 h, medium was
switched to adipogenic induction medium consisting
of DMEMehigh glucose (Invitrogen) supplemented
with 10% FBS (Biosera), 1 mmol/L DEX (Sigma-
Aldrich), 1 mmol/L indomethacin (Invitrogen), 500
mmol/L 3-isobutyl-1-methylxantine (Sigma-Aldrich)
and 10 mg/mL human recombinant insulin (Sigma-
Aldrich). For the detection of adipogenic differenti-
ation, intracellular lipid droplets were stained with
the use of oil red O solution (Sigma-Aldrich) on day
21 of differentiation.Table I. Major obstetric and demographic characteristics of
donors.
Maternal age (years) 34.7  6.1
Gestational age (weeks) 38.2  1.9
Neonatal weight (g) 3080  668Chondrogenic differentiation
CB-MSCs and AF-MSCs at passage 3 were seeded
in a 15-mL conical tube at a density of 3  105/tube
and re-suspended in chondrogenic differentiation
medium consisting of DMEMehigh glucose (Invi-
trogen) supplemented with ITS þ premix (Collab-
orative Biomedical Products, Bedford, MA, USA),
1 mmol/L pyruvate (Sigma-Aldrich), 50 mg/mL 2-
phosphateeascorbic acid (Fluka, Sigma-Aldrich),
100 nmol/L DEX (Sigma-Aldrich) and 10 ng/mL
transforming growth factor (TGF)-b1 (R and D), as
previously described by Gatto et al. (25). Cells were
grown as pellets for 3 weeks at 37C, 5% CO2.
For immunostaining experiments, cartilage pel-
lets were fixed in 4% formaldehyde in phosphate
buffer, processed for paraffin embedding and
sectioned serially. Five-micron-thick sections were
stained with hematoxylin and eosin (Sigma-Aldrich).
Primary antibodies used for immuno-localization
studies as per established protocols are listed in
Supplementary Table S1. Immuno-localization was
performed with the use of standard peroxidase/
diaminobenzidine (DAB) reaction and counter-
stained with hematoxylin. Bright-field light micro-
scopy images were obtained with the use of a Zeiss
Axiophot epifluorescence microscope (Carl Zeiss,
Oberkochen, Germany).
For the assessment of chondrogenic gene
expression profile, on days 0, 7, 14 and 21 after in-
duction, transcript levels for type II collagen (COL
II), type X collagen (COL X), SRY-box9 (SOX 9)
and aggrecan (ACAN) were analyzed by means of
Q-RT-PCR.Multiparity (%) 24 (69%)
Male newborn (%) 19 (54%)
Maternal pathologies (%) 8 (23%)
Fetal pathologies (%) 4 (11%)
Elective cesarean section (%) 27 (77%)RNA isolation and Q-RT-PCR
Total RNA was extracted with the use of TRIZOL
reagent (Invitrogen), following the manufacturer’sprotocol; 1 mg of RNA was then reverse-transcribed
with the use of a SuperScript II Reverse Transcrip-
tase kit (Invitrogen) in the presence of random hex-
amers. Quantitative real-time polymerase chain
reaction assays were performed in triplicate on an
ABI 7900 Real-Time PCR system thermal cycler
with the qPCR Mastermix (Applied Biosystems-
Invitrogen). All TaqMan gene expression assays
were provided by Applied Biosystems (Supplemen-
tary Table S2).
After having verified the stable expression of
GAPDH, this gene was included as endogenous
control. The level of each target gene was normalized
to GAPDH levels and expressed relative to the
control culture levels (DDCt method).Statistical analysis
The data were analyzed with the use of SPSS
(version 17; SPSS Inc, Chicago, IL, USA). Statistical
analysis included c2 or Fisher exact test for dichot-
omous variables, t test or one-way analysis of vari-
ance for continuous variables. A two-tailed P value
of <0.05 or an odds ratio with 95% confidence in-
tervals not inclusive of the unity was considered
significant.Results
Isolation of CB-MSCs and AF-MSCs
We collected CB and AF units from a total of 35
donors during cesarean sections at term. Obstetric
and clinical characteristics of the donor population
are shown in Table I. Twenty-four donors (69%) had
an uncomplicated pregnancy; seven pregnancies
were affected by a maternal complication (two cases
of gestational diabetes, two cases of pre-gestational
hypothyroidism, two cases of mild preeclampsia and
one case of epilepsy treated during pregnancy); three
cases had a fetal pathology (one fetus with osteogenesis
imperfecta, one with hydrocephalous and one with
multiple malformations); one pregnancy was affected
by severe preeclampsia and severe intrauterine
growth restriction.
Table II. Comparison between the major parameters of CB and
AF samples isolation.
CB (n ¼ 35) AF (n ¼ 35) P value
Adequate (%) 30/35 (86%) 20/35 (57%) 0.01
Successful (%) 12/30 (40%) 5/20 (25%) 0.4
Averall successful (%) 12/35 (34%) 5/35 (14%) 0.05
Volume (mL) 88.7  33.5 33.8  22.9 <0.001
Cellularity (106/mL) 2.5  1.6 0.5  0.8 <0.001
CFE (%) 3.17% 5.39% 0.01
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strated a consistent decrease in CB-MSCs and AF-
MSCs isolation rate when sample volume was <60
mL for CB and 20 mL for AF and when the interval
time between sampling and processing was >2 h.
According to such preliminary data and evidence
from the literature (26), CB units having a
volume <60 mL (not adequate, five of 35 units,
14%) and AF samples having a volume <20 mL or
visible contamination with blood (not adequate, 15
of 35 units, 43%) were excluded from processing
(Table II). The remaining 30 CB and 20 AF units
were considered adequate and were processed within
2 h after collection. Both volume and cellularity were
significantly lower in AF samples than in CB samples
(33.8  22.9 mL versus 88.7  33.5 mL, P < 0.001;
0.5  0.8  106 versus 2.5  1.6  106 MNCs per
milliliter, P < 0.001, respectively). Following our
protocol, we isolated MSCs from 12 of 30 processed
CB units (40%) and from five of 20 processed AF
units (25%); the difference in the overall success of
isolation between CB and AF approached signifi-
cance (34% versus 14%; P ¼ 0.05) (Table II). In two
cases, we were able to isolate both CB-MSCs and
AF-MSCs from the same donor. In the first set of
experiments, we observed a potential difference in
the number of CFU-F derived from CB and AF
specimens. Therefore, in the next set of experiments,
we quantified the colony-forming efficiency (CFE),
which is the number of CFU-F formed after seeding
MNCs, for 11 CB and 3 AF samples. The CFE was
significantly decreased in CB-MNCs (P ¼ 0.01) in
comparison with AF-MNCs (Table II).
No differences in the clinical and obstetric fea-
tures of the donors were observed between successful
and unsuccessful samples, either for CB or for AF.
No correlations were found between sample volume
or neonatal birth weight and the success rate of
isolating MSCs. Interestingly, we were able to isolate
MSCs from both CB and AF of the fetus affected by
osteogenesis imperfecta and from CB of the fetus
affected by multiple malformations.Morphology and immunophenotypic characterization of
CB-MSCs and AF-MSCs
To compare the characteristics of CB-MSCs and
AF-MSCs, we considered only the cell strains
derived from healthy donors. The MSC strains used
in the majority of the assays of our study were
selected randomly from the isolated cell lines, with 3
of 12 used for CB-MSCs and 3 of 5 used for AF-
MSCs. CB-MSC and AF-MSC colonies were
detected, respectively, at 16.2  2.6 days (range,
14e21 days, n ¼ 12) and 17.0  2.7 days (range,
15e21 days, n ¼ 5) after initial MNCs plating. Theprimary cultured cells from AF were round, spindle
or polygonal in shape and were characterized by a
more irregular morphology. Conversely, the primary
cultured CB-MSCs were a more homogeneous
population (Figure 1A). After passaging, CB-MSCs
were uniformly fibroblast-like, whereas the described
differences of AF-MSCs concerning the morphology
were observed throughout the culture (Figure 1B).
For further characterization, surface protein expres-
sion of MSCs from the three CB and the three AF
samples at passage 3 was examined by flow cytom-
etry. Selected antigens representing a CB-MSC line
and an AF-MSC line are depicted in Figure 1C.
Greater than 90% of CB-MSCs and AF-MSCs
expressed the typical MSCs marker proteins CD73,
CD105 and CD90. MSCs derived from both sources
did not display expression of hematopoietic antigens
(CD45, CD34, CD14 and HLA II). MSCs were also
negative for typical endothelial markers such as
CD31, CD144 (vascular endothelial cadherin),
VEGF-R1 and VEGF-R2 (Figure 1C and data not
shown). HLA I was expressed by a significantly lower
percentage of CB-MSCs compared with AF-MSCs
(20.0%  8.0% versus 92.6%  7.3%; P < 0.001).
This was observed for the mean fluorescence in-
tensity of HLA I expression, which was significantly
lower for CB-MSCs compared with AF-MSCs
(9.6  1.7 versus 25.5  7.1, P ¼ 0.02) (Figure 1D).
Regarding the expression of CD146, a typical surface
antigen appearing on perivascular cells and pericytes,
a wide range of differences was observed in the CB-
MSC and AF-MSC samples tested. To exclude
maternal contamination in the culture of CB-MSCs
and AF-MSCs, FISH analysis was performed to
identify XY chromosomes in MSCs isolated from a
male neonate. This test showed an XY incidence of
100%, which indicates the fetal origin of both types
of perinatal MSCs (Figure 1E).Proliferation of CB-MSCs and AF-MSCs
Adherent cells from eight CB-MSC and three AF-
MSC lines were passaged up to eight times, and PDs
were calculated. CB-MSCs and AF-MSCs divided
for an extensive period of time in vitro. No
Figure 1. Morphology, immunophenotype and cytogenetic analysis of CB-MSCs and AF-MSCs. (A) Morphology of CFU-F generated
from CB-MSCs and AF-MSCs isolated after initial plating. (B) Morphology of isolated CB-MSCs and AF-MSCs (passage 1). (C)
Representative surface immunophenotype of CB-MSCs and AF-MSCs obtained from the same donor at passage 3. Open histograms show
isotype controls and colored histograms show tested samples. (D) Comparison of the surface protein expression in MSCs derived from three
CB and three AF samples; percentage (%) of positive cells and mean fluorescence intensity (MFI) are shown. *P < 0.05; ***P < 0.001. (E)
Representative XY FISH on isolated nuclei from CB-MSCs and AF-MSCs derived from a male fetus shows the presence of both X and Y
chromosomes.
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Chondrogenic differentiation of fetal human MSCs 899differences in the proliferation rate were observed
between CB-MSCs and AF-MSCs (Figure 2A). The
karyotype of two of three CB-MSC and two of three
AF-MSC strains that were selected randomly was
analyzed at different culture passages (between PD
20 and PD 25) to evaluate the occurrence of spon-
taneous chromosomal alterations during expansion.
All analyzed samples remained genetically stable
(Figure 2B). To confirm that CB-MSCs expansion
capability was similar to that of AF-MSCs, we per-
formed a cell cycle analysis at different time points
for three AF-MSC and three CB-MSC lines. The
cell cycle distribution pattern was similar for CB-
MSCs and AF-MSCs (Figure 2C). For both AF-
MSCs and CB-MSCs, the majority of cells were in
the G0/G1 phase of the cell cycle (63%  8% and
66%  2%, respectively) at 48 h after seeding, and
the remaining cells were similarly distributed in
SG2M phase. Likewise, no differences in the cell
cycle analysis could be detected between CB-MSCs
and AF-MSCs at 96 and 144 h after seeding.Osteogenic and adipogenic differentiation capacity of
CB-MSCs and AF-MSCs
To investigate the in vitro differentiation potential,
CB-MSCs and AF-MSCs from different samples
were grown for 3 weeks in osteoblastic and adi-
pocytic differentiation medium. After osteogenic
differentiation, both CB-MSC and AF-MSC cul-
tures showed extracellular matrix mineralizationFigure 2. Proliferation, senescence and cell cycle phase distribution of C
AF-MSCs. Graph represents mean  standard deviation of eight CB
Representative Q-banded karyotype analysis of CB-MSCs and AF-MS
populations. (C) Cell cycle analysis. Percentage of cells in the different p
(PI) flow cytometric assay. Analysis was performed on at least 20,000
represents mean  standard deviation of three CB donors and three AFthat could be detected by alizarin red staining
(Figure 3A).
To further analyze osteogenic differentiation at
the molecular level, transcript levels of selected genes
involved in bone ontogeny were determined for
OPN, OTC, OTN, RUNX2, ALPL and COL IA at 7,
14 and 21 days by means of Q-RT-PCR (Figure 3C).
This analysis showed the expected expression pro-
files of the osteoblast phenotype for CB-MSCs (n ¼
6). In this cell population, ALPL, OPN, OTC, OTN
and RUNX2 showed a nearly constant upregulated
expression level. This was also the case for osteo-
genic differentiation of AF-MSCs (n ¼ 5), in which
the expression levels of ALPL, OPN, OTC, OTN and
RUNX2 were upregulated over time. The transcript
levels of the different genes analyzed showed an
extremely high variability between the different CB-
MSC and AF-MSC lines. In a single case, we were
able to evaluate osteogenic transcript levels in
differentiated CB-MSCs and AF-MSCs isolated
from the same donor, showing a similar pattern
(Figure 3D). Cells cultured in adipogenic medium
were stained with oil red O to detect intra-
cytoplasmatic lipid droplets. After adipogenic in-
duction, only 13% of CB-MSC lines (one of eight
samples analyzed) showed an adipogenic phenotype.
In this sample, however, only small oil droplets were
formed within the cells, and the frequency of positive
cells was low (Figure 3B). None of the AF-MSCs
displayed an adipogenic phenotype under differen-
tiation conditions (n ¼ 5).B-MSCs and AF-MSCs. (A) Expansion curve of CB-MSCs and
donors (continuous line) and three AF donors (dotted line). (B)
Cs in culture at standard density shows genetic stability for both
hases of the cell cycle was assessed by means of propidium iodide
cells for each sample at 48, 96 and 144 h after replating. Graph
donors.
Figure 3. Osteogenic and adipogenic differentiation of CB-MSCs and AF-MSCs. (A) Osteogenic differentiation of CB-MSCs and AF-
MSCs demonstrated by deposition of mineralized matrix detected by means of the alizarin red S method. (B) Adipogenic differentiation of
CB-MSCs is demonstrated by the accumulation of few lipid vacuoles stained by oil red O. Only one of eight CB-MSC lines was positive for
oil red O staining. (C) Expression of osteogenesis-related genes detected by RT-PCR after 7, 14 and 21 days of culture (CB-MSCs, n ¼ 6;
AF-MSCs, n ¼ 5). (D) Expression of osteogenesis-related genes in CB-MSCs and AF-MSCs isolated from the same donor.
900 A. Pievani et al.Chondrogenic differentiation capability of CB-MSCs and
AF-MSCs
To investigate the chondrogenic differentiation
capability, MSCs from both sources were cultured
in the presence of TGF-b1 to generate a solid
spherical three-dimensional tissue structure that
can be harvested and processed for histology,
immunohistochemistry and molecular analysis.
Both CB-MSCs and AF-MSCs generated typical
pellets when cultured as micromasses under chon-
drogenic conditions. After 21 days of culture, a
significant increase in pellet size was found in
CB-MSCsederived pellets. Conversely, the pellets
obtained from AF-MSCs were smaller and did not
grow significantly during the culture (section areas:
2.45  1.2 mm2 versus 0.29  0.2 mm2, respec-
tively, CB-MSC versus AF-MSC pellets, P < 0.05;
Figure 4A). Cartilage-like cells within lacunae
were observed in sections of pellets generated
from CB-MSCs but not in pellets from AF-
MSCs (Figure 4B). As expected, pellets derived
from CB-MSCs but not from AF-MSCs stained
diffusely positive for COL II, COL X and SOX-9
(Figure 4B). In addition, expression analysis of
COL II, COL X, SOX-9 and ACAN at different
time points (day 7, day 14 and day 21) confirmed
that chondrogenic differentiation was induced onlyin CB-MSCs (Figure 4C,D). In particular, the
strong upregulation of COL II expression observed
after chondrogenic induction in CB-MSCs was
absent in the case of AF-MSCs at each time point
(day 7, CB-MSCs versus AF-MSCs, P ¼ 0.00007;
day 14, CB-MSCs versus AF-MSCs, P ¼ 0.00008;
day 21, CB-MSCs versus AF-MSCs, P ¼
0.000000003; Figure 4C,D). Also ACAN and SOX-
9 were exclusively expressed by CB-MSCs pellets.
SOX-9 expression was detected at day 7 and day 14
after induction, in the earlier stages of chondro-
genesis. These data were also confirmed by the
comparison performed on cartilage pellets derived
from CB-MSCs and AF-MSCs generated from the
same donor (data not shown). Because isolation of
CB-MSCs and AF-MSCs was performed in the
presence and in the absence of DEX, respectively,
additional experiments were also performed to
evaluate whether DEX could affect cellular
commitment. These experiments demonstrated that
CB-MSCs isolated in the absence of DEX main-
tained their chondrogenic differentiation capability,
as evidenced by histology of the cartilage pellet and
expression of COL II (Figure 4E). On the other side,
the addition of DEX to AF-MSC cultures did not
improve the quality of the pellet, as evidenced by
histological and molecular data (Figure 4E).
Figure 4. Chondrogenic differentiation capability of CB-MSCs and AF-MSCs. (A) On the left, pellets generated from CB-MSCs and AF-
MSCs are shown. Hematoxylin and eosin staining of pellets induced by culture with TGF-b1 for 3 weeks. On the right, mean section area of
pellets derived fromCB-MSCs (black bar, n¼ 10, from n¼ 7 different donors) and AF-MSCs (white bar, n¼ 8, from n¼ 3 different donors)
are shown. *P< 0.05. (B) Immunostaining of CB-MSC (upper) and AF-MSC (lower) pellets with antieCOL II, antieCOLX and antieSOX
9. (C) Expression of chondrogenesis-related genes detected by RT-PCR at 7, 14 and 21 days of culture in CB-MSC pellets (pellets n ¼ 3 for
each time point, derived from three CB-MSC strains). (D) Expression of chondrogenesis-related genes detected by RT-PCR at 7, 14 and 21
days of culture in AF-MSC pellets (pellets n ¼ 4 for each time point, derived from three AF-MSC strains). (E) Histology and expression of
chondrogenesis-related genes in CB-MSCs and AF-MSCs treated or not treated with DEX (CB-MSCs without DEX, pellets n ¼ 2 derived
from two CB-MSC strains; CB-MSCs with DEX, pellets n ¼ 4 derived from three CB-MSC strains; AF-MSCs without DEX, pellets n ¼ 3
derived from three AF-MSC strains; AF-MSCs with DEX, pellets n ¼ 2 derived from one AF-MSC strain). ***P < 0.001.
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In the present study, we evaluated whether CB and
AF collected at term of pregnancy could represent
a useful and accessible source of fetal MSCs.
Furthermore, the biological properties and differen-
tiation potential of MSCs derived from these two
fetal sources were compared. When we applied strict
criteria for the selection of the samples to be pro-
cessed, we were able to isolate MSC colonies from
40% and 25% of the CB and AF units, respectively.
Likewise, Zhang et al. (26) achieved a 90% rate of
success in isolation of CB-MSCs through the use of
similar selection criteria (CB volume 90 mL and
storage time before processing 2 h). Other studieshave reported isolation yields ranging from <10% to
as high as 90%, demonstrating a lack of consensus in
the isolation and culture protocols (26e31). The
lower efficiency in AF-MSCs isolation compared
with CB-MSCs can be attributed to the heteroge-
neous population of cells from fetal origin contained
in the AF (32,33). Furthermore, the total volume
and the cellularity were significantly lower in AF
samples, which could have affected the isolation
rates. Several studies demonstrated higher efficiency
in the isolation of MSCs from preterm amniotic
fluid, usually collected during second-trimester am-
niocenteses; this difference is probably explained by
the decreased proportion of viable cells in AF with
902 A. Pievani et al.advancing gestational age (33,34). It is noteworthy,
however, that although term AF is a waste product,
which can be easily collected during delivery with no
risk for the donor, AF collected from amniocentesis
could not be considered for donation because of the
risks related to the procedure. To further improve
the success of MSCs isolation from both sources, we
evaluated whether isolation was influenced by any
features of the donor or the sample and found no
correlation with analyzed obstetric characteristics.
Considering that MSCs are already entering the
clinical arena, an extensive characterization and
standardization of reproducible in vitro and in vivo
differentiation protocols is mandatory for potential
application of these cells. We demonstrated that
although the two MSC populations can be consid-
ered similar in regard to growth kinetics, osteogenic
differentiation capacity and absence of adipogenic
differentiation, they clearly diverge in their isolation
rate, colony-forming efficiency, morphology, immu-
nophenotype (HLA-class I) and, more interestingly,
chondrogenic differentiation capacity.
First, the CFE was significantly higher in AF than
in CB samples, which suggests a higher frequency of
MSCs in the nucleated cells of AF than in those of
CB, even though the isolation rate in AF samples was
lower. Cells isolated from the two sources showed,
otherwise, a comparable proliferation rate and cell
cycle status. Both AF-MSCs and CB-MSCs
expressed the typical mesenchymal surface proteins
and lacked expression of the hematopoietic and
endothelial markers. Notably, however, significant
differences were observed in the expression of HLA-
class I, with lower expression in CB-MSCs
compared with that in AF-MSCs. However, it has
been previously demonstrated that fetal MSCs lack
or exhibit very low expression of HLA-class I
(35,36). Furthermore, AF-MSCs and CB-MSCs
successfully differentiated into osteoblasts, as
confirmed by positive alizarin red S staining and
upregulated expression of the principal osteogenic
genes. Conversely, none of the AF-MSC and only
one CB-MSC line tested showed adipogenic differ-
entiation capability. Our data are, overall, in agree-
ment with the literature (11,26,27,37) and might be
explained by the ontogenic age of these cells (38).
Only few studies have shown successful adipogenesis
in CB-MSCs, with reduced formation of lipid
droplets (6,39,40). On the other hand, sporadic work
reported successful adipogenic differentiation of AF-
MSCs isolated from second-trimester AF samples
(32,41), whereas adipogenesis of full-term AF-MSCs
has never been investigated.
To our knowledge, chondrogenic differentiation
of human AF-MSCs and CB-MSCs has never
been rigorously compared concerning the peculiarproperties of the chondroid pellets generated in vitro.
On the basis of our protocol, only CB-MSCs effi-
ciently differentiated into cartilage when they were
condensed into a single aggregate and exposed to
TGF-b1. In fact, pellets derived from CB-MSCs,
compared with AF-MSCs, were significantly larger,
showed typical cartilage-like morphology and
expressed transcripts for proteoglycans and chon-
drocyte-associated markers, such as COL II, COL X,
SOX-9 and ACAN. SOX-9 is a key transcriptional
regulator in early chondrogenesis, with an important
role in transactivating cartilage-specific genes during
chondrocyte differentiation (42,43). In our study,
gene expression profiles of SOX-9, detected at early
stages of differentiation, COL II and ACAN corre-
lated with a high in vitro potential of CB-MSCs to
differentiate into chondrocytes. On the contrary,
pellets derived from AF-MSCs expressed low levels
of cartilage-specific genes. It is also interesting to
note that in our study, the hypertrophy-associated
gene COL X was detected in the early stages of the
chondrogenic differentiation process in CB-MSCs
and in AF-MSCs. Previous studies have reported
similar data showing that human MSCs cultured in
pellets under standard chondrogenic conditions
expressed COL X transcripts throughout the pellet
culture, including in the undifferentiated MSCs
(44,45). Indeed, in AF-MSCederived pellets, cells
were not differentiated and immunohistochemistry
analysis did not reveal the presence of COL X protein
expression, which was also true for COL II and SOX-
9. In contrast, in CB-MSCs pellets, COL Xepositive
chondrocytes were detected by means of immuno-
localization. As previously described for other cell
sources, we could also confirm for CB-MSCs that in
vitro protocols of chondrogenesis produce derived
chondrocytes that undergo hypertrophy (16,46).
These data demonstrate that although MSCs from
the two sources analyzed here may be considered
similar in the majority of the biological aspects, they
clearly diverge in their chondrogenic differentiation
capability. Furthermore, in one case, we were able to
do a direct comparison of chondrogenic potential of
CB-MSCs and AF-MSCs from the same neonatal
donor, confirming that the difference shown in this
study cannot be attributed to a general difference
between donors. The use of DEX in the establish-
ment of the CB-MSCs and the absence of DEX in
the AF-MSCs isolation protocol may be another
critical factor in determining the quality of the
generated cartilage pellets. The choice to include or
exclude DEX in the isolation protocols was based on
the available literature (26). DEX has been shown to
stimulate chondrogenic differentiation of equine-,
rat- and human-derived MSCs in vitro (47). Whether
short-term exposure to DEX during isolation of
Chondrogenic differentiation of fetal human MSCs 903MSCs strains, before the subsequent exposure to a
chondrogenic induction protocol, increases the
chondrogenic potential of MSCs is undetermined.
To address this question, we evaluated whether the
addition of DEX in the isolation protocol of AF-
MSCs or the exclusion of DEX during the isolation
of CB-MSCs could change the subsequent chon-
drogenic potential. Thus, we were able to conclude
that the addition of DEX in the first week of cell
culture does not appear to be a critical factor in
determining differences between the chondrogenic
capabilities of both MSCs. The high capacity of hu-
man CB-MSCs, among various tissue-derived
MSCs, to differentiate into chondrocytes has been
described by other groups (12,20,21,26). Interest-
ingly, Berg et al. (48,49) reported that equine CB-
MSCs have superior chondrogenic potential
compared with MSCs of other biological origin,
confirming similarities between different large ani-
mals species. To our knowledge, MSCs derived from
human AF isolated at term of pregnancy have not
been extensively investigated concerning their po-
tential for cartilage regeneration (34,50). A few
studies have characterized the ability of different
multipotent stem cell populations derived from the
first or second trimester of pregnancy to undergo
chondrogenic differentiation (51e53). Following a
chondrogenic differentiation protocol similar to ours,
Kolambkar et al. (54) reported that amniotic fluide
derived stem cells were able to produce a cartilage-
like matrix in specific culture conditions, even
though less efficiently compared with BM-derived
MSCs (54). Similarly, human AF-MSCs have been
shown to produce cartilage in TGF-b3 containing
fibrin hydrogel, even if with a lower potential
compared with other MSC populations (51).
Therefore, a possible explanation for our results may
be that AF-MSC populations isolated from amniotic
fluid at term of the pregnancy have lost their chon-
drogenic potential or contain only a small proportion
of cells still able to maintain this property. Further-
more, in our study, we have adopted the most widely
applied culture system for chondrogenesis (16,17);
however, it would be interesting, for future studies,
to explore alternative strategies for the enhancement
of chondrogenesis in AF-MSCs such as increased
TGF-b concentration, addition of bone morphoge-
netic proteins and a combination of TGF-b and in-
sulin-like growth factor-1 (46). According to our
results, even if AF cells appear to contain a higher
number of clonogenic precursors compared with CB,
AF-MSCs completely fail to differentiate into carti-
lage, which shows that their multipotent capacity is
limited to osteogenic differentiation. Conversely, the
less clonogenic term CB-MSCs showed great chon-
drogenic potential, making them a good candidatestem cell population for therapeutic and biotechno-
logical applications in cartilage repair. In vivo studies
on cartilage formation and repair with the use of CB-
MSCs are now necessary to support the results ob-
tained in this study through the evaluation of in vivo
chondrogenesis, ultimately confirming their thera-
peutic potential.Acknowledgments
This work was supported by the Italian Telethon
Foundation to MS (TCP 07004). MS is Assistant
Telethon Scientist.Disclosure of interests: The authors have no
commercial, proprietary, or financial interest in the
products or companies described in this article.References
1. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R,
Mosca JD, et al. Multilineage potential of adult human
mesenchymal stem cells. Science. 1999;284:143e7.
2. Caplan AI. Mesenchymal stem cells. J Orthop Res. 1991;9:
641e50.
3. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I,
Marini F, Krause D, et al. Minimal criteria for defining
multipotent mesenchymal stromal cells: the International
Society for Cellular Therapy position statement. Cytotherapy.
2006;8:315e7.
4. Caplan AI. Why are MSCs therapeutic? New data: new
insight. J Pathol. 2009;217:318e24.
5. Sensebe L, Bourin P. Mesenchymal stem cells for therapeutic
purposes. Transplantation. 2009;87(Suppl 9):S49e53.
6. Friedenstein AJ, Chailakhjan RK, Lalykina KS. The devel-
opment of fibroblast colonies in monolayer cultures of guinea-
pig bone marrow and spleen cells. Cell Tissue Kinet. 1970;3:
393e403.
7. Gucciardo L, Lories R, Ochsenbein-Kolble N, Done E,
Zwijsen A, Deprest J. Fetal mesenchymal stem cells: isolation,
properties and potential use in perinatology and regenerative
medicine. BJOG. 2009;116:166e72.
8. Li H, Gao F, Ma L, Jiang J, Miao J, Jiang M, et al. Therapeutic
potential of in utero mesenchymal stem cell (MSCs) trans-
plantation in rat foetuses with spina bifida aperta. J Cell Mol
Med. 2012;16:1606e17.
9. Deprest J, De Coppi P. Antenatal management of isolated
congenital diaphragmatic hernia today and tomorrow: ongoing
collaborative research and development: Journal of Pediatric
Surgery Lecture. J Pediatr Surg. 2012;47:282e90.
10. Kunisaki SM. Congenital anomalies: treatment options based
on amniotic fluid-derived stem cells. Organogenesis. 2012;8:
89e95.
11. Kern S, Eichler H, Stoeve J, Kluter H, Bieback K. Compar-
ative analysis of mesenchymal stem cells from bone marrow,
umbilical cord blood, or adipose tissue. Stem Cells. 2006;24:
1294e301.
12. Rebelatto CK, Aguiar AM, Moretao MP, Senegaglia AC,
Hansen P, Barchiki F, et al. Dissimilar differentiation of
mesenchymal stem cells from bone marrow, umbilical cord
blood, and adipose tissue. Exp Biol Med. 2008;233:901e13.
904 A. Pievani et al.13. Sessarego N, Parodi A, Podesta M, Benvenuto F, Mogni M,
Raviolo V, et al. Multipotent mesenchymal stromal cells from
amniotic fluid: solid perspectives for clinical application.
Haematologica. 2008;93:339e46.
14. Campagnoli C, Roberts IA, Kumar S, Bennett PR,
Bellantuono I, Fisk NM. Identification of mesenchymal stem/
progenitor cells in human first-trimester fetal blood, liver, and
bone marrow. Blood. 2001;98:2396e402.
15. in ’t Anker PS, Noort WA, Scherjon SA, Kleijburg-van der
Keur C, Kruisselbrink AB, van Bezooijen RL, et al. Mesen-
chymal stem cells in human second-trimester bone marrow,
liver, lung, and spleen exhibit a similar immunophenotype but
a heterogeneous multilineage differentiation potential. Hae-
matologica. 2003;88:845e52.
16. Johnstone B, Hering TM, Caplan AI, Goldberg VM,
Yoo JU. In vitro chondrogenesis of bone marrow-derived
mesenchymal progenitor cells. Exp Cell Res. 1998;238:
265e72.
17. Mackay AM, Beck SC, Murphy JM, Barry FP,
Chichester CO, Pittenger MF. Chondrogenic differentiation
of cultured human mesenchymal stem cells from marrow.
Tissue Eng. 1998;4:415e28.
18. Heng BC, Cao T, Lee EH. Directing stem cell differentiation
into the chondrogenic lineage in vitro. Stem Cells. 2004;22:
1152e67.
19. Koga H, Muneta T, Nagase T, Nimura A, Ju YJ, Mochizuki T,
et al. Comparison of mesenchymal tissues-derived stem cells
for in vivo chondrogenesis: suitable conditions for cell therapy
of cartilage defects in rabbit. Cell Tissue Res. 2008;333:
207e15.
20. de Mara CS, Duarte AS, Sartori-Cintra AR, Luzo AC,
Saad ST, Coimbra IB. Chondrogenesis from umbilical cord
blood cells stimulated with BMP-2 and BMP-6. Rheumatol
Int. 2013;33:121e8.
21. Wang JF, Wang LJ, Wu YF, Xiang Y, Xie CG, Jia BB, et al.
Mesenchymal stem/progenitor cells in human umbilical cord
blood as support for ex vivo expansion of CD34(þ) hemato-
poietic stem cells and for chondrogenic differentiation. Hae-
matologica. 2004;89:837e44.
22. Fernandes AM, Herlofsen SR, Karlsen TA, Kuchler AM,
Floisand Y, Brinchmann JE. Similar properties of chon-
drocytes from osteoarthritis joints and mesenchymal stem
cells from healthy donors for tissue engineering of articular
cartilage. PLoS One. 2013;8:e62994.
23. Tavecchio M, Natoli C, Ubezio P, Erba E, D’Incalci M.
Dynamics of cell cycle phase perturbations by trabectedin
(ET-743) in nucleotide excision repair (NER)-deficient and
NER-proficient cells, unravelled by a novel mathematical
simulation approach. Cell Prolif. 2007;40:885e904.
24. Ubezio P. Microcomputer experience in analysis of flow
cytometric DNA distributions. Comput Programs Biomed.
1985;19:159e66.
25. Gatto F, Redaelli D, Salvade A, Marzorati S, Sacchetti B,
Ferina C, et al. Hurler disease bone marrow stromal cells
exhibit altered ability to support osteoclast formation. Stem
Cells Dev. 2012;21:1466e77.
26. Zhang X, Hirai M, Cantero S, Ciubotariu R, Dobrila L,
Hirsh A, et al. Isolation and characterization of mesenchymal
stem cells from human umbilical cord blood: reevaluation of
critical factors for successful isolation and high ability to
proliferate and differentiate to chondrocytes as compared to
mesenchymal stem cells from bone marrow and adipose tis-
sue. J Cell Biochem. 2011;112:1206e18.
27. Bieback K, Kern S, Kluter H, Eichler H. Critical parameters
for the isolation of mesenchymal stem cells from umbilical
cord blood. Stem Cells. 2004;22:625e34.28. Erices A, Conget P, Minguell JJ. Mesenchymal progenitor
cells in human umbilical cord blood. Br J Haematol. 2000;
109:235e42.
29. Secco M, Zucconi E, Vieira NM, Fogaca LL, Cerqueira A,
Carvalho MD, et al. Multipotent stem cells from umbilical
cord: cord is richer than blood! Stem Cells. 2008;26:146e50.
30. Morigi M, Rota C, Montemurro T, Montelatici E, Lo
Cicero V, Imberti B, et al. Life-sparing effect of human cord
blood-mesenchymal stem cells in experimental acute kidney
injury. Stem Cells. 2010;28:513e22.
31. Manca MF, Zwart I, Beo J, Palasingham R, Jen LS,
Navarrete R, et al. Characterization of mesenchymal stromal
cells derived from full-term umbilical cord blood. Cytother-
apy. 2008;10:54e68.
32. Kim J, Lee Y, Kim H, Hwang KJ, Kwon HC, Kim SK, et al.
Human amniotic fluid-derived stem cells have characteristics
of multipotent stem cells. Cell Prolif. 2007;40:75e90.
33. Gosden CM. Amniotic fluid cell types and culture. Br Med
Bull. 1983;39:348e54.
34. In’t Anker PS, Scherjon SA, Kleijburg-van der Keur C, de
Groot-Swings GM, Claas FH, Fibbe WE, et al. Isolation of
mesenchymal stem cells of fetal or maternal origin from hu-
man placenta. Stem Cells. 2004;22:1338e45.
35. Chen PM, Yen ML, Liu KJ, Sytwu HK, Yen BL. Immuno-
modulatory properties of human adult and fetal multipotent
mesenchymal stem cells. J Biomed Sci. 2011;18:49.
36. Zhang ZY, Teoh SH, Chong MS, Schantz JT, Fisk NM,
Choolani MA, et al. Superior osteogenic capacity for bone
tissue engineering of fetal compared with perinatal and adult
mesenchymal stem cells. Stem Cells. 2009;27:126e37.
37. Karagianni M, Brinkmann I, Kinzebach S, Grassl M,
Weiss C, Bugert P, et al. A comparative analysis of the adi-
pogenic potential in human mesenchymal stromal cells from
cord blood and other sources. Cytotherapy. 2013;15:76e88.
38. Moerman EJ, Teng K, Lipschitz DA, Lecka-Czernik B. Aging
activates adipogenic and suppresses osteogenic programs in
mesenchymal marrow stroma/stem cells: the role of PPAR-
gamma2 transcription factor and TGF-beta/BMP signaling
pathways. Aging Cell. 2004;3:379e89.
39. Lee OK, Kuo TK, Chen WM, Lee KD, Hsieh SL, Chen TH.
Isolation of multipotent mesenchymal stem cells from um-
bilical cord blood. Blood. 2004;103:1669e75.
40. Goodwin HS, Bicknese AR, Chien SN, Bogucki BD,
Quinn CO, Wall DA. Multilineage differentiation activity by
cells isolated from umbilical cord blood: expression of bone,
fat, and neural markers. Biol Blood Marrow Transplant.
2001;7:581e8.
41. De Gemmis P, Lapucci C, Bertelli M, Tognetto A, Fanin E,
Vettor R, et al. A real-time PCR approach to evaluate adi-
pogenic potential of amniotic fluid-derived human mesen-
chymal stem cells. Stem Cells Dev. 2006;15:719e28.
42. Huang W, Chung UI, Kronenberg HM, de Crombrugghe B.
The chondrogenic transcription factor Sox9 is a target of
signaling by the parathyroid hormone-related peptide in the
growth plate of endochondral bones. Proc Natl Acad Sci U S
A. 2001;98:160e5.
43. Ng LJ, Wheatley S, Muscat GE, Conway-Campbell J,
Bowles J, Wright E, et al. SOX9 binds DNA, activates tran-
scription, and coexpresses with type II collagen during
chondrogenesis in the mouse. Dev Biol. 1997;183:108e21.
44. Mwale F, Stachura D, Roughley P, Antoniou J. Limitations of
using aggrecan and type X collagen as markers of chondro-
genesis in mesenchymal stem cell differentiation. J Orthop
Res. 2006;24:1791e8.
45. Barry F, Boynton RE, Liu B, Murphy JM. Chondrogenic
differentiation of mesenchymal stem cells from bone marrow:
Chondrogenic differentiation of fetal human MSCs 905differentiation-dependent gene expression of matrix compo-
nents. Exp Cell Res. 2001;268:189e200.
46. Boeuf S, Richter W. Chondrogenesis of mesenchymal stem
cells: role of tissue source and inducing factors. Stem Cell Res
Ther. 2010;1:31.
47. Derfoul A, Perkins GL, Hall DJ, Tuan RS. Glucocorticoids
promote chondrogenic differentiation of adult human
mesenchymal stem cells by enhancing expression of cartilage
extracellular matrix genes. Stem Cells. 2006;24:1487e95.
48. Berg L, Koch T, Heerkens T, Bessonov K, Thomsen P,
Betts D. Chondrogenic potential of mesenchymal stromal
cells derived from equine bone marrow and umbilical cord
blood. Vet Comp Orthop Traumatol. 2009;22:363e70.
49. Buechli ME, Lamarre J, Koch TG. MicroRNA-140 expres-
sion during chondrogenic differentiation of equine cord
blood-derived mesenchymal stromal cells. Stem Cells Dev.
2013;22:1288e96.
50. You Q, Tong X, Guan Y, Zhang D, Huang M, Zhang Y, et al.
The biological characteristics of human third trimester am-
niotic fluid stem cells. J Int Med Res. 2009;37:105e12.
51. Park JS, Shim MS, Shim SH, Yang HN, Jeon SY, Woo DG,
et al. Chondrogenic potential of stem cells derived fromamniotic fluid, adipose tissue, or bone marrow encapsulated in
fibrin gels containing TGF-beta3. Biomaterials. 2011;32:
8139e49.
52. Kunisaki SM, Fuchs JR, Steigman SA, Fauza DO.
A comparative analysis of cartilage engineered from different
perinatal mesenchymal progenitor cells. Tissue Eng. 2007;13:
2633e44.
53. Preitschopf A, Zwickl H, Li K, Lubec G, Joo G, Rosner M,
et al. Chondrogenic differentiation of amniotic fluid stem cells
and their potential for regenerative therapy. Stem Cell Rev.
2012;8:1267e74.
54. Kolambkar YM, Peister A, Soker S, Atala A, Guldberg RE.
Chondrogenic differentiation of amniotic fluid-derived stem
cells. J Mol Histol. 2007;38:405e13.
Supplementary data
Supplementary data related to this article can be
found at http://dx.doi.org/10.1016/j.jcyt.2014.02.
008.
